Fresenius Medical Care AG/€FME

05:30
09:10
12:45
16:25
20:00
1D1W1MYTD1Y5YMAX

About Fresenius Medical Care AG

Fresenius Medical Care, listed under the ticker FME, is a global provider of dialysis services and products for individuals diagnosed with chronic kidney failure. Founded in 1996 and headquartered in Bad Homburg, Germany, the company operates in the healthcare sector. Beyond dialysis, Fresenius Medical Care offers a range of other services, including hospital management and related healthcare services, advancing its position as a comprehensive healthcare provider internationally.

Ticker

€FME
Sector

Primary listing

XETRA

Employees

112,445

FME Metrics

BasicAdvanced
€13B
20.72
€2.23
0.88
€1.44
3.11%

What the Analysts think about FME

Analyst ratings (Buy, Hold, Sell) for Fresenius Medical Care AG stock.

Bulls say / Bears say

Fresenius Medical Care beat Q1 2025 estimates with revenues of €4.88 billion and adjusted operating income of €457 million, driving a 2.7% share price increase and confirming its full-year outlook (Reuters).
The company unveiled a €1 billion share buyback programme, signaling confidence in its cash-flow generation and a commitment to enhanced shareholder returns (Reuters).
Management reaffirmed strong profitability targets, projecting high-teens to high-twenties percent operating income growth for 2025 with an 11–12% margin and a mid-teens operating margin by 2030, supported by €300 million in cost savings initiatives (Reuters).
A proposed class action lawsuit filed in Colorado alleges Fresenius Medical Care conspired with DaVita to inflate dialysis treatment costs through anti-competitive practices, exposing the company to significant legal liabilities and reputational damage (Reuters).
The €1 billion share buyback announced in June, combined with planned annual capital expenditures of up to €1 billion, may strain free cash flow and limit Fresenius Medical Care’s flexibility for strategic investments or R&D (Reuters).
High flu and cold cases in February led to missed dialysis treatments in the U.S. during Q1, underscoring Fresenius Medical Care’s operational vulnerability to external health-related disruptions and volume volatility (Reuters).
Data summarised monthly by Lightyear AI. Last updated on 29 Sept 2025.

FME Financial Performance

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

FME Earnings Performance

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Market data provided by CBOE Europe and Deutsche Börse.

Buy €FME

Sign up or log in to buy
Capital at risk
Market closed

Upcoming events

No upcoming events
FAQs